The cooperation between hMena overexpression and HER2 signalling in breast cancer

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Di Modugno, Francesca ^a   Mottolese, Marcella ^a   DeMonte, Lucia ^b   Trono, Paola ^a   Balsamo, Michele ^a,c   Conidi, Andrea ^a,d   Melucci, Elisa ^a   Terrenato, Irene ^a   Belleudi, Francesca ^e   Torrisi, Maria Rosaria ^f   Alessio, Massimo ^b   Santoni, Angela ^f   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; PROTEIN HMENA; PROTEIN KINASE B; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ENAH PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOGENESIS; PROGNOSIS; PROTEIN PHOSPHORYLATION; BREAST TUMOR; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROFILAMENT PROTEINS; MIDDLE AGED; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 78651225884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015852     Document Type: Article

References (36)

1. Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer Suppl 4: S3-8.
2. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer Suppl 4: S9-15.
3. Feldner JC, Brandt BH (2002) Cancer cell motility-on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 272: 93-108.
4. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-16.
5. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100: 8933-8.
6. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-87.
7. Yin HL, Janmey PA (2003) Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol 65: 761-89.
8. Mouneimne G, Soon L, DesMarais V, Sidani M, Song X, et al. (2004) Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol 166: 697-708.
9. Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79.
10. Margadant C, van Opstal A, Boonstra J (2007) Focal adhesion signaling and actin stress fibers are dispensable for progression through the ongoing cell cycle. J Cell Sci 120: 66-76.
11. Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, et al. (2004) Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 109: 909-18.
12. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB (2003) Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 19: 541-64.
13. Scott JA, Shewan AM, den Elzen NR, Loureiro JJ, Gertler FB, et al. (2006) Ena/ VASP proteins can regulate distinct modes of actin organization at cadherinadhesive contacts. Mol Biol Cell 17: 1085-95.
14. Boëda B, Briggs DC, Higgins T, Garvalov BK, Faddena AJ, et al. (2007) Tes, a specific Mena interacting partner, breaks the rules for EVH1 binding. Mol Cell 28: 1071-82.
15. Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novello F, et al. (2006) The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res 12: 1470-8.
16. Di Modugno F, DeMonte L, Balsamo M, Bronzi G, Nicotra MR, et al. (2007) Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res 67: 2657-65.
17. +11a isoform serves as a marker of epithelial phenotype and sensitivity to EGFR inhibition in human pancreatic cancer cell lines. Clin Cancer Res 14: 4943-50.
18. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP (2009) ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33: 591-601.
19. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96.
20. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendhal P, et al. (2010) Identification of subtypes in human epidermal growth factor receptor 2- positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28: 1813-20.
21. Perou CM, Sørlie T, Eisen MB, Van De Rijnm, Jeffery SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-52.
22. Janssens K, De Kimpe L, Balsamo M, Vandoninck S, Vandenheede JR, et al. (2009) Characterization of EVL-I as a protein kinase D substrate. Cell Signal 21: 282-92.
23. Bachmann C, Fischer L, Walter U, Reinhard M (1999) The EVH2 domain of the vasodilator-stimulated phosphoprotein mediates tetramerization, F-actin binding, and actin bundle formation. J Biol Chem 274: 23549-57.
24. Siegel PM, Ryan ED, Cardiff RD, Muller WJ (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18: 2149-64.
25. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-75.
26. Cao Z, Wu X, Yen L, Sweeney C, Carraway KL, 3rd (2007) Neuregulininduced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 27: 2180-8.
27. Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, et al. (2010) Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. Oncogene 29: 4682-4692.
28. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, et al. (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15: 813-28.
29. Goswami S, Philippar U, Sun D, Patsialou A, Avraham J, et al. (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26: 153-9.
30. Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, et al. (2008) OMERO Group. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 19: 1706-12.
31. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, et al. (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103: 1770-7.
32. Nisticò P, De Berardinis P, Morrone S, Alonzi T, Buono C, et al. (1994) Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3- independent pathway. J Clin Invest 94: 1426-31.
33. Conti A, Ricchiuto P, Iannaccone S, Sferrazza B, Cattaneo A, et al. (2005) Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies. Proteomics 5: 4558-67.
34. Yamagata A, Kristensen DB, Takeda Y, Miyamoto Y, Okada K, et al. (2002) Mapping of phosphorylated proteins on two-dimensional polyacrylamide gels using protein phosphatase. Proteomics 2: 1267-76.
35. Tavassoli FA, Devilee P (2003) Tumors of the Breast. Edited by Tavassoli FA, Devilee P, eds. Lyon, France: IARC Press.
36. Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, et al. (2006) Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. Oncologist 8: 878-86.